Anticoagulation in Dialysis Patients

First-Line Anticoagulant Options

The American Society of Hematology (ASH) recommends argatroban, danaparoid, or bivalirudin for patients with acute heparin-induced thrombocytopenia (HIT) requiring dialysis 3
Argatroban is an ideal option for dialysis patients due to its lack of renal clearance and clinically insignificant dialytic clearance by high-flux membranes 2
Danaparoid has been successfully used during renal replacement therapy despite its dependence on renal clearance, with extensive clinical experience supporting its use 1

Prospective studies of argatroban in patients undergoing continuous renal replacement therapy showed low rates of new thrombosis (0%-4%) and major bleeding (0%-6%) 2
A retrospective review of danaparoid use in dialysis patients with HIT showed thrombosis of either the patient or the hemodialysis circuit in only 7% of cases, with major bleeding in 6% 2
Argatroban's pharmacokinetic profile in patients with renal failure is similar to that in patients with normal renal function, making it particularly suitable for this population 4

Bivalirudin is suggested as an alternative by ASH guidelines if argatroban or danaparoid are not available 3
Regional citrate anticoagulation is recommended for patients with a past history of HIT who require ongoing renal replacement therapy 1, 2

Renal clearance: Argatroban is preferred for its lack of renal clearance, making it safer in patients with kidney failure 2, 4
Monitoring requirements: The ability to monitor the anticoagulant effect varies between agents and may influence selection 3
Cost considerations: The ASH guidelines acknowledge that the cost of argatroban may be prohibitive at some clinical centers 2

Avoid using heparin or low-molecular-weight heparin in patients with a history of HIT due to risk of recurrence 1, 2
Be cautious with lepirudin in dialysis patients due to its prolonged half-life and potential for accumulation between dialysis sessions 2